Is United Therapeutics Corporation (UTHR) a Buy, Sell, or Hold?
NASDAQ : UTHR
United Therapeutics Corporation
$524.7 USD
$1.07 (0.2%)
- Volume
- 402.26K
- Average Volume
- 479.44K
- Market Capitalization
- $22.27B
- P/E Ratio
- 17.93
- Dividend Yield
- 0.00%
- Price Target
- $625.00
- Year High
- $609.35
- Year Low
- $272.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.79
Company Overview
NASDAQ
Martine A. Rothblatt
Biotechnology
Healthcare
UTHR
1400
US
USD
Liquidity Metrics
0.00
4.79
4.50
1.79
0.00
Sales & Valuation
$3.18B
7.03
3.87
21.90
23.38
Profitability
$27.86
$1.33B
40.61%
50.75%
19.24%
19.17%
P/E Metrics
17.93
2.25
2.25
Analyst Price Target & Rating
$625.00
$735.00
$516.00
4/5
30 Analysts
-16.05%
Financial Health Scores
20.07
6/9
$2.27B
$6.71B
$813.1M
$1.63B
Key Metrics (TTM)
$21.15B
6.67
12.34
4.79
19.24%
18.81%
5.65%
4.58%
$300.56
-239 days
Company Executives
| Name | Title |
|---|---|
| Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation |
| Harrison Silvers | Manager of Investor Relations |
| Michael I. Benkowitz | President & Chief Operating Officer |
| Paul A. Mahon | Executive Vice President, General Counsel & Corporate Secretary |
| Holly Hobson | Associate Vice President of Human Resources |
| Martine A. Rothblatt | Founder, Chairman & Chief Executive Officer |
| James C. Edgemond | Chief Financial Officer & Treasurer |
| Gil Golden | Senior Vice President & Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About United Therapeutics Corporation (NASDAQ:UTHR) Stock
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. U ... nituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
2026-07-29 06:30:00
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full results of its ADVANCE OUTCOMES study, available here. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Ralinepag reduced the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?
2026-07-28 17:07:01
9,500 shares were disposed of for ~$5.0 million based on a weighted average execution price of $530.42 on July 27, 2026. The transaction represents a 1% reduction in total equity holdings, leaving the insider with ~669,000 shares across direct and indirect accounts.
Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?
2026-07-24 12:00:26
Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.
Atika Capital Management LLC Invests $7.32 Million in United Therapeutics Corporation $UTHR
2026-07-24 03:51:13
Atika Capital Management LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 12,350 shares of the biotechnology company's stock, valued at approximately $7,323,000. United Therapeutics makes up 0.9% of Atika Capital Management
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
2026-07-23 07:00:00
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor Dzau, M.D.,
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
2026-07-23 06:30:00
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026.Dr. Dzau recently completed a 12-year tenure as President of the National Academy of Medicine (NAM) and formerly served as Chancellor for Health Affairs at Duke University, President and CEO of the Duke University Health System, and Chairman of Medicine at.
2026-07-22 07:00:00
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 a.m. Eastern Time.United Therapeutics will host a public webcast on Wednesday, August 5, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of th.
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?
2026-07-22 06:45:33
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
Frequently Asked Questions
-
What is the current United Therapeutics Corporation (UTHR) stock price?
-
United Therapeutics Corporation(NASDAQ:UTHR) stock price is $524.7 in the last trading session. During the trading session, UTHR stock reached the peak price of $609.35 while $272.12 was the lowest point it dropped to. The percentage change in UTHR stock occurred in the recent session was 0.2% while the dollar amount for the price change in UTHR stock was $1.07.
-
UTHR's industry and sector of operation?
-
The NASDAQ listed UTHR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of UTHR?
-
Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation
Harrison Silvers | Manager of Investor Relations
Michael I. Benkowitz | President & Chief Operating Officer
Paul A. Mahon | Executive Vice President, General Counsel & Corporate Secretary
Holly Hobson | Associate Vice President of Human Resources -
How many employees does UTHR have?
-
Number of UTHR employees currently stands at 1400. UTHR operates from 1040 Spring Street, Silver Spring, MD 20910, US.
-
Link for UTHR official website?
-
Official Website of UTHR is: https://www.unither.com
-
How do I contact UTHR?
-
UTHR could be contacted at phone #301 608 9292 and can also be accessed through its website. UTHR operates from 1040 Spring Street, Silver Spring, MD 20910, US.
-
How many shares of UTHR are traded daily?
-
The average number of UTHR shares traded daily for last 3 months was 479.44K.
-
What is the market cap of UTHR currently?
-
The market value of UTHR currently stands at $22.27B with its latest stock price at $524.7